The U.S. Supreme Court has blocked a lower court ruling that would have cut off nationwide mail and telehealth access to the abortion medication mifepristone. The 7-2 ruling on the court’s “shadow docket” preserves the FDA’s 2023 policy that lifted a requirement to prescribe mifepristone in person. The ACLU’s Reproductive Freedom Project said in a statement, “While it is good news that, for now, patients can continue to get this safe medication by mail and at pharmacies as they have for more than five years, we all know abortion opponents are continuing their unpopular and baseless attacks.”